Investigators at Avalere Health Report New Data on Atopic Dermatitis (Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact …): Skin Diseases and Conditions – Atopic Dermatitis

2026 JUN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Skin Diseases and Conditions - Atopic Dermatitis have been published. According to news reporting out of Washington, District of Columbia, by NewsRx editors, research stated, “Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US. Potent systemic treatments, such as tralokinumab, are needed to treat patients with moderate-to-severe disease who have experienced inadequate symptom control using topical therapies.”

Our news journalists obtained a quote from the research from Avalere Health, “Novel systemic treatments can not only provide effective relief for these patients but can also be cost saving. To evaluate the budgetary implications of tralokinumab as a treatment for moderate-to-severe AD in a hypothetical US commercial healthcare plan with 1 million (M) members. A budget impact model was developed to estimate the difference in total systemic treatment costs between two scenarios: one in which dupilumab, lebrikizumab, nemolizumab, abrocitinib and upadacitinib are assumed to be the only treatments available, and one in which tralokinumab is assumed to be an additional option. The analysis took the perspective of a US commercial payer and estimated total treatment costs over a 3-year time horizon. Patients were distributed to treatments based on forecasted market share data and could switch from dupilumab to other systemic treatments in the model at any time. Switching rates were also informed using forecasting data. Adult patients receiving tralokinumab and adults or adolescents receiving lebrikizumab and nemolizumab could switch to a lower frequency administration schedule if they achieved clear or almost clear skin, reducing the number of doses received and consequently the treatment costs. Treatment costs were informed by 2025 wholesale acquisition costs. Total costs when tralokinumab was not available were estimated to be $21.0 M, $27.7 M and $35.9 M in years 1-3, respectively. When tralokinumab was available, estimates were $20.6 M (D-0.5 M) in year 1, $26.6 M (D-1.1 M) in year 2 and $34.1 M (D-1.8 M) in year 3. Therefore, availability of tralokinumab led to cumulative cost savings of $3.4 M across all 3 years ($2.3 M in adults and $1.1 M in adolescents). Cumulative treatment costs per plan member at year 3 also reduced from $84.68 to $81.26 (D-3.42) due to tralokinumab. Lastly, cumulative per patient treatment costs across the 653 patients estimated to receive systematic therapy over the 3 years reduced from $129,794 to $124,556 when tralokinumab was available.”

According to the news editors, the research concluded: “Tralokinumab is a cost-saving therapy when used for the treatment of moderate-to-severe AD in both adult and adolescent populations, with cost savings driven by competitive skin clearance rates, low monthly treatment costs and flexible dosing options in adults (i.e., Q2W -> Q4W).”

This research has been peer-reviewed.

For more information on this research see: Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis. Journal of Comparative Effectiveness Research, 2026. Journal of Comparative Effectiveness Research can be contacted at: Becaris Publishing, 43 Kneesworth Street, Royston, United Kingdom.

Our news journalists report that additional information may be obtained by contacting Linnea Houde, Avalere Health, 1201 New York Avenue NW, Suite 1000, Washington, DC 20005, United States. Additional authors for this research include Reece Grindley, Aseel Bin Sawad, Sanjeev Balu and Shannon Schneider.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.57264/cer-2026-0042. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Comparative Effectiveness Research is: Becaris Publishing, 43 Kneesworth Street, Royston, United Kingdom.

(Our reports deliver fact-based news of research and discoveries from around the world.)